JP2016503301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503301A5 JP2016503301A5 JP2015542308A JP2015542308A JP2016503301A5 JP 2016503301 A5 JP2016503301 A5 JP 2016503301A5 JP 2015542308 A JP2015542308 A JP 2015542308A JP 2015542308 A JP2015542308 A JP 2015542308A JP 2016503301 A5 JP2016503301 A5 JP 2016503301A5
- Authority
- JP
- Japan
- Prior art keywords
- pca
- category
- biomarker
- biomarkers
- composite value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims description 44
- 206010060862 Prostate cancer Diseases 0.000 claims description 34
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 21
- 102100038358 Prostate-specific antigen Human genes 0.000 claims description 16
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 10
- 102100025142 Beta-microseminoprotein Human genes 0.000 claims description 8
- 230000001689 kallikreinlike Effects 0.000 claims description 7
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims 18
- 239000003446 ligand Substances 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 241001610351 Ipsa Species 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 235000006694 eating habits Nutrition 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 101150039612 rpsK gene Proteins 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 12
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 5
- 108010044434 Alpha-methylacyl-CoA racemase Proteins 0.000 description 4
- 102100040410 Alpha-methylacyl-CoA racemase Human genes 0.000 description 4
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 4
- 108010020169 beta-microseminoprotein Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102100038356 Kallikrein-2 Human genes 0.000 description 3
- 101710176220 Kallikrein-2 Proteins 0.000 description 3
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 108010007355 Glutathione S-Transferase pi Proteins 0.000 description 2
- 102000007648 Glutathione S-Transferase pi Human genes 0.000 description 2
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 2
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000009732 beta-microseminoprotein Human genes 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1251312-3 | 2012-11-20 | ||
| SE1251312 | 2012-11-20 | ||
| SE1350600-1 | 2013-05-16 | ||
| SE1350600 | 2013-05-16 | ||
| PCT/EP2013/074259 WO2014079865A1 (en) | 2012-11-20 | 2013-11-20 | Method for indicating a presence or non-presence of aggressive prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018189147A Division JP2019049559A (ja) | 2012-11-20 | 2018-10-04 | 侵攻性前立腺癌の存在または不存在を判定する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503301A JP2016503301A (ja) | 2016-02-04 |
| JP2016503301A5 true JP2016503301A5 (enExample) | 2017-01-05 |
Family
ID=49619938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542308A Pending JP2016503301A (ja) | 2012-11-20 | 2013-11-20 | 侵攻性前立腺癌の存在または不存在を判定する方法 |
| JP2018189147A Pending JP2019049559A (ja) | 2012-11-20 | 2018-10-04 | 侵攻性前立腺癌の存在または不存在を判定する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018189147A Pending JP2019049559A (ja) | 2012-11-20 | 2018-10-04 | 侵攻性前立腺癌の存在または不存在を判定する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10431326B2 (enExample) |
| EP (2) | EP3327146A1 (enExample) |
| JP (2) | JP2016503301A (enExample) |
| KR (1) | KR20150110477A (enExample) |
| AU (1) | AU2013349801B2 (enExample) |
| BR (1) | BR112015011359B1 (enExample) |
| CA (2) | CA2891392C (enExample) |
| DK (1) | DK2922967T3 (enExample) |
| ES (1) | ES2667326T3 (enExample) |
| IL (1) | IL238724A0 (enExample) |
| MY (1) | MY182773A (enExample) |
| RU (1) | RU2675370C2 (enExample) |
| WO (1) | WO2014079865A1 (enExample) |
| ZA (1) | ZA201503460B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3312749T3 (pl) | 2012-03-05 | 2024-10-07 | Oy Arctic Partners Ab | Metody i aparaty do prognozowania ryzyka raka gruczołu krokowego i objętości gruczołu krokowego |
| RU2669809C2 (ru) | 2012-11-20 | 2018-10-16 | Пхадиа Аб | Способ прогноза для индивидуумов с раком предстательной железы |
| CA2940445C (en) | 2014-03-11 | 2021-11-30 | Phadia Ab | Method for detecting a solid tumor cancer |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| PE20170298A1 (es) | 2014-03-28 | 2017-04-18 | Opko Diagnostics Llc | Composiciones y metodos relacionados con el diagnostico del cancer de prostata |
| JP6749337B2 (ja) | 2015-03-27 | 2020-09-02 | オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ | 前立腺抗原標準およびその使用 |
| US9858665B2 (en) * | 2015-04-03 | 2018-01-02 | Regents Of The University Of Minnesota | Medical imaging device rendering predictive prostate cancer visualizations using quantitative multiparametric MRI models |
| HK1247824A1 (zh) * | 2015-04-29 | 2018-10-05 | 欧普科诊断有限责任公司 | 用於主动监控前列腺癌的组合物和方法 |
| WO2017164699A1 (ko) * | 2016-03-24 | 2017-09-28 | 서울대학교병원 (분사무소) | 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발 |
| ES2688213T3 (es) * | 2016-07-15 | 2018-10-31 | Proteomedix Ag | Método para detectar proteínas en muestras humanas y usos de dichos métodos |
| FI3577237T3 (fi) * | 2017-02-01 | 2023-08-29 | Phadia Ab | Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia |
| KR102093453B1 (ko) * | 2018-01-08 | 2020-03-25 | (주)인실리코젠 | 체형 및 대사 감수성 snp 마커 및 진단정보 제공방법 |
| WO2019144112A1 (en) | 2018-01-22 | 2019-07-25 | Phadia Ab | Method for the harmonization of assay results |
| IT201800021394A1 (it) * | 2018-12-28 | 2020-06-28 | Daniela Terracciano | Metodo in vitro per la diagnosi del cancro alla prostata |
| US11633146B2 (en) | 2019-01-04 | 2023-04-25 | Regents Of The University Of Minnesota | Automated co-registration of prostate MRI data |
| US11631171B2 (en) | 2019-01-10 | 2023-04-18 | Regents Of The University Of Minnesota | Automated detection and annotation of prostate cancer on histopathology slides |
| CN109628564B (zh) * | 2019-02-25 | 2022-02-01 | 北京市理化分析测试中心 | 一种用于检测snp多态性的引物组和利用引物组检测snp多态性的方法 |
| KR102371654B1 (ko) * | 2019-02-28 | 2022-03-08 | 주식회사 프로카젠 | 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102068667B1 (ko) * | 2019-02-28 | 2020-01-21 | 주식회사 프로카젠 | 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102068666B1 (ko) * | 2019-02-28 | 2020-02-11 | 주식회사 프로카젠 | 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102371655B1 (ko) * | 2019-02-28 | 2022-03-08 | 주식회사 프로카젠 | 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| IT202000029948A1 (it) * | 2020-12-04 | 2022-06-04 | Nib Biotec S R L | Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età |
| JP7641532B2 (ja) * | 2020-08-28 | 2025-03-07 | 国立研究開発法人理化学研究所 | 前立腺がんの検査方法 |
| GB2599198B (en) * | 2021-06-15 | 2022-12-07 | A3P Biomedical Ab | A method for determining an appropriate time interval for further diagnostic testing for prostate cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219840A1 (en) | 2002-05-24 | 2003-11-27 | Mikolajczyk Stephen D. | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| FR2934698B1 (fr) | 2008-08-01 | 2011-11-18 | Commissariat Energie Atomique | Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede. |
| CA2750062A1 (en) * | 2009-01-19 | 2010-07-22 | Katrin Stedronsky | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
| US20120121618A1 (en) | 2009-02-12 | 2012-05-17 | Dana-Farber Cancer Institute, Inc. | Predicting And Treating Prostate Cancer |
| EP2576835A4 (en) * | 2010-06-01 | 2013-10-30 | Univ Laval | PROGNOSTIC MARKERS FOR THE REPRODUCTION OF PROSTATE CANCER |
| US9732389B2 (en) | 2010-09-03 | 2017-08-15 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| US20120202888A1 (en) | 2010-10-08 | 2012-08-09 | The Brigham And Women's Hospital, Inc. | Biomarkers of prostate cancer and predicting mortality |
| US20120150032A1 (en) * | 2010-12-13 | 2012-06-14 | Julius Gudmundsson | Sequence Variants Associated with Prostate Specific Antigen Levels |
| US20150094221A1 (en) | 2012-05-16 | 2015-04-02 | Phadia Ab | Method for Indicating the Presence or Non-Presence of Prostate Cancer |
| RU2669809C2 (ru) | 2012-11-20 | 2018-10-16 | Пхадиа Аб | Способ прогноза для индивидуумов с раком предстательной железы |
-
2013
- 2013-11-20 EP EP17210720.3A patent/EP3327146A1/en not_active Withdrawn
- 2013-11-20 WO PCT/EP2013/074259 patent/WO2014079865A1/en not_active Ceased
- 2013-11-20 MY MYPI2015701578A patent/MY182773A/en unknown
- 2013-11-20 BR BR112015011359-1A patent/BR112015011359B1/pt not_active IP Right Cessation
- 2013-11-20 CA CA2891392A patent/CA2891392C/en active Active
- 2013-11-20 CA CA3092807A patent/CA3092807C/en active Active
- 2013-11-20 AU AU2013349801A patent/AU2013349801B2/en active Active
- 2013-11-20 JP JP2015542308A patent/JP2016503301A/ja active Pending
- 2013-11-20 US US14/443,970 patent/US10431326B2/en active Active
- 2013-11-20 EP EP13792689.5A patent/EP2922967B1/en active Active
- 2013-11-20 KR KR1020157015113A patent/KR20150110477A/ko not_active Ceased
- 2013-11-20 ES ES13792689.5T patent/ES2667326T3/es active Active
- 2013-11-20 RU RU2015124054A patent/RU2675370C2/ru active
- 2013-11-20 DK DK13792689.5T patent/DK2922967T3/en active
-
2015
- 2015-05-10 IL IL238724A patent/IL238724A0/en unknown
- 2015-05-18 ZA ZA2015/03460A patent/ZA201503460B/en unknown
-
2018
- 2018-10-04 JP JP2018189147A patent/JP2019049559A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503301A5 (enExample) | ||
| JP2016508026A5 (enExample) | ||
| AU2021232712B2 (en) | Method for detecting a solid tumor cancer | |
| Halvorsen et al. | Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab | |
| Stephan et al. | Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2: ERG gene fusion with the serum [− 2] proprostate-specific antigen–based prostate health index for detection of prostate cancer | |
| RU2015124054A (ru) | Способ выявления присутствия или отсутствия агрессивного рака предстательной железы | |
| Leligdowicz et al. | Validation of two multiplex platforms to quantify circulating markers of inflammation and endothelial injury in severe infection | |
| ES2694409T3 (es) | Método de pronóstico para individuos con cáncer de próstata | |
| Xu et al. | Serum C-reactive protein and risk of lung cancer: a case–control study | |
| Na et al. | Performance of serum prostate‐specific antigen isoform [‐2] proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital‐based biopsy population | |
| US20150094221A1 (en) | Method for Indicating the Presence or Non-Presence of Prostate Cancer | |
| JP2015523569A5 (enExample) | ||
| Wu et al. | Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus–related hepatocellular carcinoma | |
| Harrison et al. | Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful? | |
| JP2022179483A (ja) | 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法 | |
| JP2020505928A5 (enExample) | ||
| Liang et al. | Prospective evaluation of operating characteristics of prostate cancer detection biomarkers | |
| Do et al. | Detection of sFas, sCD137, and IL-27 cytokines as potential biomarkers for hepatocellular carcinoma diagnosis | |
| CN105051206B (zh) | 用于指示侵袭性前列腺癌的存在或不存在的方法 |